secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2022-11-29T23:59:59+00:00
Accession:  0001493152-22-033887
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos receives Nasdaq deficiency notice for late Q3 10-Q; expects to file in weeks
--------------------------------------------------------------------------------

- Nasdaq notified Vivos of non-compliance with Listing Rule 5250(c)(1) for late Q3 2022 Form 10-Q.
- This is the second delinquency; Q2 2022 filing was also late and previously disclosed.
- Company expects to submit a compliance plan to Nasdaq allowing until February 20, 2023 to regain compliance.
- Revenue recognition issues (ASC 606) have been resolved; Q1 2022 10-Q restated on November 25, 2022.
- Vivos plans to file both Q2 and Q3 2022 10-Qs in the coming weeks, which would cure the deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315222033887/0001493152-22-033887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315222033887/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-033887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer